Unusual presentation of luminal breast carcinoma metastatic to the brain and coma: a case report of dramatic response to abemaciclib and literature review.

IF 4.2 2区 医学 Q2 ONCOLOGY Therapeutic Advances in Medical Oncology Pub Date : 2025-03-28 eCollection Date: 2025-01-01 DOI:10.1177/17588359251317847
Maria Rosaria Valerio, Calogero Cipolla, Martina Greco, Chiara Mesi, Francesca Modica, Vittorio Gebbia, Giuseppa Scandurra, Daniela Sambataro
{"title":"Unusual presentation of luminal breast carcinoma metastatic to the brain and coma: a case report of dramatic response to abemaciclib and literature review.","authors":"Maria Rosaria Valerio, Calogero Cipolla, Martina Greco, Chiara Mesi, Francesca Modica, Vittorio Gebbia, Giuseppa Scandurra, Daniela Sambataro","doi":"10.1177/17588359251317847","DOIUrl":null,"url":null,"abstract":"<p><p>Patients with luminal breast cancer (BC) may develop central nervous system metastases in 20%-40% of cases. Radiation or surgical therapy represents the cornerstone of treating central nervous system metastases. Meanwhile, the best practice for metastatic luminal BC involves using cyclin-dependent kinase 4/6 inhibitors combined with endocrine therapy. To our knowledge, this is the first case to report a dramatic response of breast metastases to abemaciclib plus endocrine therapy without radiation therapy, particularly in a patient who presented with seizures and sudden coma. She received brain surgery to control a large bleeding metastasis. Abemaciclib was crushed and diluted in water for administration via the nasogastric tube, while an upfront fulvestrant was given since aromatase inhibitors cannot be diluted. Beyond the radiological response, the clinical improvement was notable, with complete symptom recovery to the point where she is again working. Our paper supports the activity of abemaciclib in brain metastases from luminal BC and includes a review of the medical literature. Further investigation is warranted in this clinical setting.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"17 ","pages":"17588359251317847"},"PeriodicalIF":4.2000,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11954534/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Medical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17588359251317847","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Patients with luminal breast cancer (BC) may develop central nervous system metastases in 20%-40% of cases. Radiation or surgical therapy represents the cornerstone of treating central nervous system metastases. Meanwhile, the best practice for metastatic luminal BC involves using cyclin-dependent kinase 4/6 inhibitors combined with endocrine therapy. To our knowledge, this is the first case to report a dramatic response of breast metastases to abemaciclib plus endocrine therapy without radiation therapy, particularly in a patient who presented with seizures and sudden coma. She received brain surgery to control a large bleeding metastasis. Abemaciclib was crushed and diluted in water for administration via the nasogastric tube, while an upfront fulvestrant was given since aromatase inhibitors cannot be diluted. Beyond the radiological response, the clinical improvement was notable, with complete symptom recovery to the point where she is again working. Our paper supports the activity of abemaciclib in brain metastases from luminal BC and includes a review of the medical literature. Further investigation is warranted in this clinical setting.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
异常表现的腔内乳腺癌转移到大脑和昏迷:1例报告戏剧性的反应阿贝马昔利布和文献复习。
腔内乳腺癌(BC)患者在20%-40%的病例中可能发生中枢神经系统转移。放射或手术治疗是治疗中枢神经系统转移的基础。同时,转移性管腔BC的最佳做法是使用周期蛋白依赖性激酶4/6抑制剂联合内分泌治疗。据我们所知,这是第一例报道乳腺癌转移灶对阿贝马昔利布联合内分泌治疗无放射治疗有显著反应的病例,特别是在出现癫痫发作和突然昏迷的患者中。她接受了脑部手术来控制大面积出血转移。Abemaciclib粉碎并在水中稀释,通过鼻胃管给药,而由于芳香酶抑制剂不能稀释,因此预先给予氟维司汀。除了放射反应外,临床改善也很显著,症状完全恢复到再次工作的地步。我们的论文支持abemaciclib在管腔BC脑转移中的活性,并包括对医学文献的回顾。在此临床背景下需要进一步的研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
8.20
自引率
2.00%
发文量
160
审稿时长
15 weeks
期刊介绍: Therapeutic Advances in Medical Oncology is an open access, peer-reviewed journal delivering the highest quality articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of cancer. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in medical oncology, providing a forum in print and online for publishing the highest quality articles in this area. This journal is a member of the Committee on Publication Ethics (COPE).
期刊最新文献
Retraction: Long noncoding RNA LSINCT5 promotes endometrial carcinoma cell proliferation, cycle, and invasion by promoting the Wnt/β-catenin signaling pathway via HMGA2. Stromal tumor-associated eosinophils predict therapeutic resistance and survival in locally advanced tongue squamous cell carcinoma after neoadjuvant therapy. Clinical characteristics and outcomes in patients with early-onset locally advanced rectal cancer. The relationship between genetic mutations and organ metastasis in non-small cell lung cancer. A computer vision method to evaluate tumor-infiltrating lymphocytes and multiparametric modeling of neoadjuvant systemic therapy response in breast cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1